Nicholas Hall’s OTC.NewDirections is an e-newsletter produced in association with Jenson R+ delivered weekly and includes an inspired mix of global consumer healthcare news and commentary from the viewpoint of the self-care industry, backed by insights from industry experts.

Headlines

1

TRACKER PRODUCT OF THE WEEK: NESTLE UNIT OFFERS CBD FORMULAS |

USA: Nestle-owned Atrium Innovations' Garden of Life has introduced Dr Formulated CBD formulas backed by third-party certification (by Labdoor) to be THC-free. Garden of Life created the line with neurologist Dr David Perlmutter, the driving force behind all Dr Formulated products ... 

read more >>

2

ACTIVIA MAKES SMOOTH EXPANSION TO NEW SHELF CATEGORY |

UK: Danone is expanding its Activia line into a new category and shelf positioning with Activia Live Culture Smoothies. Each 250ml bottle delivers a source of calcium and contains billions of exclusive live cultures to provide protein and fibre with no added sugar ... 

read more >>

3

NEW PROBIOTIC SHOT MAY HELP PREVENT HANGOVER |

USA: ZBiotics has launched a functional beverage that contains a genetically engineered Bacillus subtilis strain (B. subtilis ZB183) that claims to help mitigate the after-effects of drinking alcohol. The strain was developed by the company and is said to help break down acetaldehyde – an alcohol metabolite associated with feelings of hangover – in the gut without altering the gut microbiome ... 

read more >>

OTC.NewDirections provides you with the latest developments in a number of key areas:

New Ingredients

New Ingredients

Trademarked or patented ingredients & molecules, licensing opportunities and brands seeking partners

New
Products

New Products

Important launches, line extensions & adjacencies (registered OTCs and supplements) with innovative formulations, claims or indications – includes stand-out contributions from our sister service, OTC New Products Tracker

Innovation

Innovation

Technological and scientific advancements, delivery methods, early-stage developments

Medical Devices

Medical Devices

Substance-based devices, mechanical devices, diagnostics

Medical Research

Medical Research

Scientific studies, clinical trials

Switch

Switch

Rx-to-OTC switch, reverse switch, access to medicines

Digital
Health

Digital Health

Mobile & Web apps, wearables, internet connected devices, telehealth

Agency
News

Agency News

Approvals, collaborations, regulatory affairs, guidance

Health Claims & Safety

Health Claims & Safety

New or additional claims approved for specific ingredients or products, disallowed advertising claims, plus alerts and warnings

Cannabis

Cannabis

Key regulatory developments and product launches as this new category evolves in specific markets

E-cigarettes

E-cigarettes

Scientific research, opinion, product development, regulation

In Focus

In Focus

Spotlight on a specific topic

Why subscribe to OTC.NewDirections

1.

Extensive coverage of the World’s innovation, scientific and regulatory environment

2.

Written in collaboration with Jenson R+ and supported by commentary from industry specialists

3.

Quick access to the most important developments

OTC.NewDirections covers all major regions providing you with the essential information to keep you informed of the latest developments affecting your business.

The website also provides you with the opportunity to take a deeper look at trends via the news archive, Supplements Focus and Switch List.

Prepared by our expert team:

Nicola Watts

Nicola Watts
Editor
OTC.NewDirections

Nina Stimpson

Nina Stimson
VP & Consulting Editor
OTC.NewDirections

Kristen McEwan

Kristen McEwan
Assistant Editor
OTC.NewDirections

  • Delivered direct to your inbox every Tuesday, bringing you the latest breaking news and commentary in a concise and easy to read format.
  • Go direct to further information:
    • - clinical trial results
    • - regulatory documents and reports that are of interest to your business.
  • Access our archive of 11,000 stories reaching back to 2012
  • Access the Extras: Supplements Focus and the Switch List